Fundies. English
OKYO Pharma Limited
EDGAR161 filing records in this dataset, filed from 2022-03-04 to 2026-10-06. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 14.6 million USD Source
Exact value
14594268 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- Not available
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-06.
Financial data available through: 2026-03-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- operating income: No compatible figures in this window
- net income: No compatible figures in this window
- Operating cash flow: 7 of 11 periods available· newest 2026-03-31
- Capital expenditure: 5 of 11 periods available· newest 2026-03-31
- Total assets: 6 of 11 periods available· newest 2026-03-31
- Total liabilities: 6 of 11 periods available· newest 2026-03-31
- Current assets: 6 of 11 periods available· newest 2026-03-31
- Current liabilities: 6 of 11 periods available· newest 2026-03-31
- Cash and cash equivalents: 7 of 11 periods available· newest 2026-03-31
- long term debt: No compatible figures in this window
- shares outstanding: No compatible figures in this window
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Operating cash flow
−USD 4.09 millionPrior period
−USD 1.81 million
–
Current period
−USD 5.9 million
–
Exact inputs and evidence
-5900000 − -1810931 = -4089069 USD
-1810931 USD · 2024-04-01 – 2025-03-31
Inspect prior input Prior source-5900000 USD · 2025-04-01 – 2026-03-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+403.3%Prior period
USD 1,208
–
Current period
USD 6,080
–
Exact inputs and evidence
6080 − 1208 = 4872 USD
1208 USD · 2024-04-01 – 2025-03-31
Inspect prior input Prior source6080 USD · 2025-04-01 – 2026-03-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Net income.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2020 2019-04-01 – 2020-03-31 | Unavailable Not reported for this period. | −USD 1.2 million Exact valueExact value: -1202066 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2021 2020-04-01 – 2021-03-31 | Unavailable Not reported for this period. | −USD 1.6 million Exact valueExact value: -1600198 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 6,943 Exact valueExact value: 6943 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.61 million Calculation and evidence-1600198 − 6943 USD Exact free cash flow: -1607141 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2022 2021-04-01 – 2022-03-31 | Unavailable Not reported for this period. | −USD 5.47 million Exact valueExact value: -5468065 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1,669 Exact valueExact value: 1669 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 5.47 million Calculation and evidence-5468065 − 1669 USD Exact free cash flow: -5469734 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2023 2022-04-01 – 2023-03-31 | Unavailable Not reported for this period. | −USD 7.7 million Exact valueExact value: -7695242 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 5,916 Exact valueExact value: 5916 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 7.7 million Calculation and evidence-7695242 − 5916 USD Exact free cash flow: -7701158 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2023-04-01 – 2024-03-31 | Unavailable Not reported for this period. | −USD 9.49 million Exact valueExact value: -9490537 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2024-04-01 – 2025-03-31 | Unavailable Not reported for this period. | −USD 1.81 million Exact valueExact value: -1810931 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1,208 Exact valueExact value: 1208 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.81 million Calculation and evidence-1810931 − 1208 USD Exact free cash flow: -1812139 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2026 2025-04-01 – 2026-03-31 | Unavailable Not reported for this period. | −USD 5.9 million Exact valueExact value: -5900000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 6,080 Exact valueExact value: 6080 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 5.91 million Calculation and evidence-5900000 − 6080 USD Exact free cash flow: -5906080 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
161 filings · 279 latest values · 279 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001849296, 1849296, edgar:1849296
Also known as OKYO Pharma Limited, OKYO PHARMA LIMITED, OKYO Pharma Limited, OKYO Pharma Ltd